Anti-IFN-γ therapy was inefficacious in SLE and resulted in more adverse events and fatigue; however, the HRQoL data was not formally captured [38]; in spite of this, oncology patients receiving anti-IFN-γ therapy had a similar increase of adverse events and demonstrated worsened HRQoL [38,39,40]. The gene discussed is IFNG; the disease is systemic lupus erythematosus.